Meta-analysis demonstrates that somatic mutations are more common than germline mutations, BRCA2 mutations are more common than BRCA1 mutations in both metastatic patients and patients with any stage PC, and that the frequency of BRCA mutations is higher in the series including only patients with metastatic disease than in the whole population of all patients studied regardless of stage. Here, BRCA2 is linked to metastatic neoplasm.